However, distinctly to Nav‐Gal, DT2216 has not been designed for targeting senescent cells, but for reducing thrombocytopenia (as platelets are characterized by poor VHL E3 ligase expression) while maintaining anti‐cancer properties. This evidence concerns the gene VHL and cancer.